CIAM
RXRX icon

Caitong International Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Caitong International Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.8K Buy
+13,615
New +$52.6K 0.01% 836
2025
Q4 		– Sell
-18,659
Closed -$91.1K – 2310
2025
Q3 		$91.1K Buy
18,659
+9,640
+107% +$50.6K 0.06% 187
2025
Q2 		$45.6K Buy
9,019
+4,446
+97% +$21.8K 0.03% 283
2025
Q1 		$24.2K Buy
4,573
+4,309
+1,632% +$31.4K 0.02% 708
2024
Q4 		$1.78K Buy
+264
New +$1.77K ﹤0.01% 1194

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caitong International Asset Management's RXRX Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 13,615 shares worth $41.8K. The stake represents 0.01% of the portfolio and ranks #836 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in RXRX as recently as Q3 2025.

Caitong International Asset Management first reported a position in RXRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $91.1K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Caitong International Asset Management held 13,615 shares of Recursion Pharmaceuticals worth $41.8K as of Q1 2026.
  • Recursion Pharmaceuticals was a new Caitong International Asset Management position in Q1 2026.
  • Recursion Pharmaceuticals made up 0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #836 holding.
  • Caitong International Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Caitong International Asset Management's Recursion Pharmaceuticals position peaked at $91.1K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.